1. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial. (1st June 2020) Authors: Blauvelt, A.; Papp, K.; Gottlieb, A.; Jarell, A.; Reich, K.; Maari, C.; Gordon, K.B.; Ferris, L.K.; Langley, R.G.; Tada, Y.; Lima, R.G.; Elmaraghy, H.; Gallo, G.; Renda, L.; Park, S.Y.; Burge, R.; Bagel, J.; Vender, Ronald; Lomaga, Mark A.; Delorme, Isabelle Journal: British journal of dermatology Issue: Volume 182:Number 6(2020) Page Start: 1348 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate‐to‐severe disease. Issue 11 (9th June 2021) Authors: Sims, Jonathan T.; Chang, Ching‐Yun; Higgs, Richard E.; Engle, Sarah M.; Liu, Yushi; Sissons, Sean E.; Rodgers, George H.; Simpson, Eric L.; Silverberg, Jonathan I.; Forman, Seth B.; Janes, Jonathan M.; Colvin, Stephanie C.; Guttman‐Yassky, Emma Journal: Experimental dermatology Issue: Volume 30:Issue 11(2021) Page Start: 1650 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗